The product Aromasin, manufactured by Prime Pharma, was submitted for independent testing by panda0435, an individual consumer. The sample, identified by batch number Unknown, was analyzed by Janoshik Analytical to verify its potency. The analysis showed that the sample contained 9.89 mg of Exemestane per tablet, which represents 98.9% of the labeled claim of 10 mg.
Testing was initiated on 20 January 2025, with the sample received on 21 January 2025. The analysis was conducted on 24 January 2025. While the measured concentration is slightly below the labeled dose, it reflects reasonable manufacturing quality for this batch. Independent third-party testing across multiple batches is recommended to ensure consistency across product lines.
This report aims to support harm reduction by promoting transparency and helping consumers make informed decisions about their use of pharmaceutical products.
Detailed Report
Product Overview
- Manufacturer: Prime Pharma
- Product Name: Aromasin
- Active Ingredient: Exemestane
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #56340
- Testing Ordered: 20 January 2025
- Sample Received: 21 January 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: panda0435 (Individual)
- Analysis Paid For By: panda0435 (Individual)
Testing Results
| Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|
| 10 mg (as per label) | 9.89 mg | 98.9% | -1.1% |
Verification Details
- Verification URL: https://janoshik.com/tests/56340_BXBMGCCU43J7
Evaluation of Individual-Submitted Testing
The analysis confirms that the Aromasin (Exemestane 10 mg) sample contains 9.89 mg of Exemestane per tablet, which is slightly under the labeled dose of 10 mg (by -1.1%). This small discrepancy is within acceptable limits for pharmaceutical products, suggesting good manufacturing quality for this batch.
Given that the sample was submitted by panda0435, an individual consumer with no commercial ties, there is no bias due to commercial interests. However, since the sample was submitted by a consumer rather than a third-party testing organization, it is important to acknowledge that resellers or manufacturers may selectively provide certain batches for testing. Additional independent third-party testing across multiple batches is recommended to confirm the consistency of the product line.
Conclusion
The analysis of Aromasin (Exemestane 10 mg) confirms that the product contains 9.89 mg per tablet, which is slightly below the labeled claim of 10 mg. This result falls within acceptable pharmaceutical tolerances and reflects consistent quality for the tested batch. For a comprehensive assessment of the entire product line, additional independent testing across various batches is advised.
This report serves to educate consumers and promote harm reduction by enabling informed decision-making regarding pharmaceutical products.
Disclaimer
This report is for educational and harm reduction purposes. The results are specific to the batch tested and may not reflect the quality of other batches. Although panda0435 has no commercial interests, readers are encouraged to evaluate testing data alongside third-party or independent results to form a complete understanding. Always consult healthcare professionals and adhere to local regulations before using such products.
